A Randomized Controlled Trial of an Eczema Care Plan
Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Corinna J Rea1, Katherine D Tran2, Maria Jorina3
1Division of General Pediatrics, Boston, Mass; Harvard Medical School, Boston, Mass.
Insights
An eczema care plan improved provider documentation and management for pediatric eczema patients. However, the eczema care plan did not significantly decrease eczema severity or improve quality of life compared to usual care.
Area of Science:
- Pediatric Dermatology
- Clinical Trial Research
- Healthcare Management
Background:
- Eczema significantly impacts children's quality of life.
- Effective management strategies are crucial in pediatric primary care.
- Current management may lack comprehensive, standardized approaches.
Purpose of the Study:
- To evaluate if an eczema care plan (ECP) enhances provider documentation and management of pediatric eczema.
- To determine if an ECP reduces eczema severity.
- To assess if an ECP improves patient quality of life (QOL) in primary care.
Main Methods:
- A randomized controlled trial involving children aged 1 month to 16 years with eczema.
- Intervention group received an ECP; control group received usual care.
- Validated eczema severity (POEM) and QOL (IDQOL/CDLQI) scales were used pre- and post-intervention.
Main Results:
- Providers using the ECP were more likely to recommend comprehensive plans, bleach baths, and wet wraps.
- Documentation of written care plans increased significantly in the intervention group.
- Both groups showed improvement in eczema severity and QOL, with no significant difference between groups.
Conclusions:
- The eczema care plan improved provider documentation and adherence to recommended management strategies.
- Despite improved documentation, the ECP did not lead to statistically significant improvements in eczema severity or patient quality of life.
- Further research may be needed to optimize ECPs for clinical outcomes.
Objective:
To test whether an eczema care plan (ECP) would improve provider documentation and management, decrease eczema severity, and increase patient quality of life (QOL) in the pediatric primary care setting.
Methods:
We conducted a randomized controlled trial from June 2015 to September 2016 at a large hospital-based pediatric primary care clinic. Participants included children from 1 month to 16 years of age with a diagnosis of eczema. The intervention group received the ECP and the control group received usual care. Both groups completed a validated eczema severity scale (Patient-Oriented Eczema Measure [POEM]) and a QOL scale (Infant's Dermatitis Quality of Life Index [IDQOL]) or Children's Dermatology Life Quality Index [CDLQI]) before the visit and again ~1 month later.
Results:
A total of 211 caregivers completed both the pre- and postintervention surveys (100 control group and 111 intervention group [94% completion]). Intervention group providers were more likely to recommend a comprehensive "step-up" plan (88%) vs 28%; P < .001, bleach baths (45%) vs 9%; P < .001, and wet wraps (50%) vs 7%; P < .001. They were also more likely to document providing a written plan to families (80%) vs 2%; P < .001. In the intervention and control groups, eczema severity and QOL improved between the pre- and postintervention periods. However, there was not a significant difference between the groups on either measure: POEM difference -0.8, 95% confidence interval (CI) -3.2 to 1.7; IDQOL difference -0.1, 95% CI -1.8 to 1.6; CDLQI difference 0.8, 95% CI -0.9 to 2.6.
Conclusions:
Intervention group providers documented more comprehensive eczema care than control group providers. Although patients improved on all measures in the postintervention period, the ECP did not augment that improvement.
More Related Videos
Related Concept Videos
Planning Nursing Care I
Planning Nursing Care II
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Random Error

